EncompaSSc:MTX-474 用于弥漫性皮肤系统性硬化症(dcSSc)受试者的评估
一项2期随机、双盲、安慰剂对照研究,旨在评估MTX-474治疗弥漫性皮肤系统性硬化症(dcSSc)患者的安全性和有效性
A Phase 2 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-474 in Participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc)
研究概览
详细说明
Participants with dcSSc who meet the study's inclusion and exclusion criteria will be randomly assigned in a 3:2 ratio to receive MTX-474 or a matching placebo by intravenous (IV) infusion. Concomitant use of one of the approved dcSSc therapies (immunosuppressive therapy, systemic glucocorticoids or other antifibrotic agents) is permitted under certain criteria. Participants randomized to the MTX-474 arm of the study will receive an IV infusion every 4 weeks, beginning at Day 0 and ending at Week 20. The End of Treatment Visit will occur at Week 24, and a Safety Follow-Up Visit will occur at Week 28, 8 weeks after the final infusion. mRSS assessments will occur at Screening, Baseline, and at all subsequent treatment visits up to and including Week 24. Spirometry will be performed at screening and Weeks 12. HRCT will be performed at screening and week 24. DLCO will be performed at Screening. Skin biopsies will be performed at Baseline and Week 12. Participants will have blood drawn for safety assessment and to assess Ephrin receptor levels at Screening, Baseline and every 4 weeks until Week 28. Blood will be drawn for serum PK analyses relative to the first and last doses of MTX-474.
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习联系方式
- 姓名:Jeffrey Bornstein, MD
- 电话号码:803 (617) 936-0960
- 邮箱:jeffrey@mediartx.com
学习地点
-
-
-
Ancona、意大利、60126
- 尚未招聘
- EncompaSSc site in Ancona, Italy
-
接触:
- EncompaSSc contact
- 电话号码:617-802-6568
- 邮箱:EncompaSSc@mediartx.com
-
Catania、意大利、95123
- 尚未招聘
- EncompaSSc site in Catania, Italy
-
接触:
- EncompaSSc contact
- 电话号码:617-802-6568
- 邮箱:EncompaSSc@mediartx.com
-
Genoa、意大利、16132
- 尚未招聘
- EncompaSSc site in Genoa, Italy
-
接触:
- EncompaSSc contact
- 电话号码:617-802-6568
- 邮箱:EncompaSSc@mediartx.com
-
Milan、意大利、20122
- 尚未招聘
- EncompaSSc site in Milan, Italy
-
接触:
- EncompaSSc contact
- 电话号码:617-802-6568
- 邮箱:EncompaSSc@mediartx.com
-
Modena、意大利、41124
- 尚未招聘
- EncompaSSc site in Modena, Italy
-
接触:
- EncompaSSc contact
- 电话号码:617-802-6568
- 邮箱:EncompaSSc@mediartx.com
-
Roma、意大利、00128
- 尚未招聘
- EncompaSSc site in Roma, Italy
-
接触:
- EncompaSSc contact
- 电话号码:617-802-6568
- 邮箱:EncompaSSc@mediartx.com
-
-
-
-
-
Auckland、新西兰、2025
- 招聘中
- Aotearoa Clinical Trials
-
首席研究员:
- Mark Sapsford
-
接触:
- Research Department
- 电话号码:617-802-6568
- 邮箱:info@aotearoatrials.nz
-
Hamilton、新西兰、3204
- 招聘中
- Waikato Hospital
-
接触:
- EncompaSSc contact
- 电话号码:617-802-6568
- 邮箱:EncompaSSc@mediartx.com
-
首席研究员:
- Kamal Solanki
-
-
-
-
-
La Tronche、法国、38700
- 尚未招聘
- EncompaSSc site in La Tronche, France
-
接触:
- EncompaSSc contact
- 电话号码:617-802-6568
- 邮箱:EncompaSSc@mediartx.com
-
Montpellier、法国、34090
- 尚未招聘
- EncompaSSc site in Montpellier, France
-
接触:
- EncompaSSc contact
- 电话号码:617-802-6568
- 邮箱:EncompaSSc@mediartx.com
-
Paris、法国、75014
- 尚未招聘
- EncompaSSc site in Paris, France
-
接触:
- EncompaSSc contact
- 电话号码:617-802-6568
- 邮箱:EncompaSSc@mediartx.com
-
Strasbourg、法国、67000
- 尚未招聘
- EncompaSSc site in Strasbourg, France
-
接触:
- EncompaSSc contact
- 电话号码:617-802-6568
- 邮箱:EncompaSSc@mediartx.com
-
Toulouse、法国、31059
- 尚未招聘
- EncompaSSc site in Toulouse, France
-
接触:
- EncompaSSc contact
- 电话号码:617-802-6568
- 邮箱:EncompaSSc@mediartx.com
-
Vandœuvre-lès-Nancy、法国、54500
- 尚未招聘
- EncompaSSc site in Vandœuvre-lès-Nancy, France
-
接触:
- EncompaSSc contact
- 电话号码:617-802-6568
- 邮箱:EncompaSSc@mediartx.com
-
-
-
-
-
Bydgoszcz、波兰、85-168
- 尚未招聘
- EncompaSSc site in Bydgoszcz, Poland
-
接触:
- EncompaSSc contact
- 电话号码:617-802-6568
- 邮箱:EncompaSSc@mediartx.com
-
Nowa Sól、波兰、67-100
- 尚未招聘
- EncompaSSc site in Nowa Sól, Poland
-
接触:
- EncompaSSc contact
- 电话号码:617-802-6568
- 邮箱:EncompaSSc@mediartx.com
-
Warsaw、波兰、00-874
- 尚未招聘
- EncompaSSc site in Warszawa, Poland
-
接触:
- EncompaSSc contact
- 电话号码:617-802-6568
- 邮箱:EncompaSSc@mediartx.com
-
Warsaw、波兰、02-507
- 尚未招聘
- EncompaSSc site in Warszawa, Poland
-
接触:
- EncompaSSc contact
- 电话号码:617-802-6568
- 邮箱:EncompaSSc@mediartx.com
-
-
-
-
Queensland
-
Southport、Queensland、澳大利亚、4222
- 招聘中
- Griffith University (Clinical Trial Unit)
-
接触:
- EncompaSSc contact
- 电话号码:617-802-6568
- 邮箱:EncompaSSc@mediartx.com
-
首席研究员:
- Gerald Tracey
-
Woolloongabba、Queensland、澳大利亚、4102
- 招聘中
- Veracity Clinical Research
-
首席研究员:
- Lynda Spelman
-
接触:
- EncompaSSc contact
- 电话号码:617-802-6568
- 邮箱:EncompaSSc@mediartx.com
-
-
Victoria
-
Heidelberg、Victoria、澳大利亚、3084
- 招聘中
- Austin Health
-
首席研究员:
- Jessica Leung
-
接触:
- Rheumatology Department
- 电话号码:617-802-6568
- 邮箱:rheumatology@austin.org.au
-
-
-
-
-
Brasov、罗马尼亚、500283
- 尚未招聘
- EncompaSSc site in Brasov, Romania
-
接触:
- EncompaSSc contact
- 电话号码:617-802-6568
- 邮箱:EncompaSSc@mediartx.com
-
Bucharest、罗马尼亚、030463
- 尚未招聘
- EncompaSSc site in Bucharest, Romania
-
接触:
- EncompaSSc contact
- 电话号码:617-802-6568
- 邮箱:EncompaSSc@mediartx.com
-
Bucharest、罗马尼亚、041303
- 尚未招聘
- EncompaSSc site in Bucharest, Romania
-
接触:
- EncompaSSc contact
- 电话号码:617-802-6568
- 邮箱:EncompaSSc@mediartx.com
-
Timișoara、罗马尼亚、300133
- 尚未招聘
- EncompaSSc site in Timişoara, Romania
-
接触:
- EncompaSSc contact
- 电话号码:617-802-6568
- 邮箱:EncompaSSc@mediartx.com
-
-
-
-
Arizona
-
Phoenix、Arizona、美国、85054
- 尚未招聘
- EncompaSSc site in Phoenix, AZ
-
接触:
- EncompaSSc contact
- 电话号码:617-802-6568
- 邮箱:EncompaSSc@mediartx.com
-
-
California
-
La Jolla、California、美国、92037
- 尚未招聘
- EncompaSSc site in La Jolla, CA
-
接触:
- EncompaSSc contact
- 电话号码:617-802-6568
- 邮箱:EncompaSSc@mediartx.com
-
Loma Linda、California、美国、92350
- 尚未招聘
- EncompaSSc site in Loma Linda, CA
-
接触:
- EncompaSSc contact
- 电话号码:617-802-6568
- 邮箱:EncompaSSc@mediartx.com
-
Los Angeles、California、美国、90095
- 招聘中
- University of California Los Angeles Scleroderma Center
-
首席研究员:
- Elizabeth Volkmann
-
接触:
- Nahal Ghanoongooi
- 电话号码:617-802-6568
- 邮箱:nghanoongooi@mednet.ucla.edu
-
Newport Beach、California、美国、92663
- 招聘中
- NewportNativeMD, Inc.
-
首席研究员:
- Ryan Klein
-
接触:
- Jennifer Gonzolez
- 电话号码:617 802 6568
- 邮箱:jennifer@newportnativemd.com
-
Palo Alto、California、美国、94304
- 尚未招聘
- EncompaSSc site in Palo Alto, CA
-
接触:
- EncompaSSc contact
- 电话号码:617-802-6568
- 邮箱:EncompaSSc@mediartx.com
-
-
Colorado
-
Aurora、Colorado、美国、80045
- 招聘中
- University of Colorado Center for Lungs/Breathing/Scleroderma Clinic
-
接触:
- Chong Pedrick
- 电话号码:617-802-6568
- 邮箱:CHONG.PEDRICK@CUANSCHUTZ.EDU
-
首席研究员:
- Melissa Griffith
-
-
Florida
-
Clearwater、Florida、美国、33765
- 招聘中
- Clinical Research of West Florida
-
首席研究员:
- Rodney Daniel
-
接触:
- Amber Tipker
- 电话号码:617 802 6568
- 邮箱:atipker@crwf.com
-
Sarasota、Florida、美国、34239
- 招聘中
- Sarasota Arthritis Center
-
首席研究员:
- Jesse Boodoo
-
接触:
- Research Department
- 电话号码:1-941-365-0770 ext:1052
- 邮箱:research@arthritiscenters.net
-
Tampa、Florida、美国、33606
- 招聘中
- Clinical Research of West Florida
-
首席研究员:
- John Carter
-
接触:
- Michelle Villela
- 电话号码:617 802 6568
- 邮箱:mvillela@crwf.com
-
-
Kansas
-
Kansas City、Kansas、美国、66103
- 尚未招聘
- EncompaSSc site in Kansas City, KS
-
接触:
- EncompaSSc contact
- 电话号码:617-802-6568
- 邮箱:EncompaSSc@mediartx.com
-
-
Maryland
-
Baltimore、Maryland、美国、21205
- 招聘中
- Johns Hopkins University
-
首席研究员:
- Laura Hummers
-
接触:
- Gwen Leatherman
- 电话号码:617 802 6568
- 邮箱:gleathe1@jh.edu
-
-
Massachusetts
-
Boston、Massachusetts、美国、02115
- 招聘中
- Brigham and Women's Hospital
-
接触:
- Joyce Shen
- 电话号码:617-802-6568
- 邮箱:jshen0@bwh.harvard.edu
-
首席研究员:
- Avery LaChance
-
Boston、Massachusetts、美国、02118
- 招聘中
- Boston Medical Center
-
接触:
- Kimberly Finch
- 电话号码:617 802 6568
- 邮箱:kimtobin@bu.edu
-
首席研究员:
- Andreea Bujor
-
-
Minnesota
-
Minneapolis、Minnesota、美国、55455
- 尚未招聘
- EncompaSSc site in Minneapolis, MN
-
接触:
- EncompaSSc contact
- 电话号码:617-802-6568
- 邮箱:EncompaSSc@mediartx.com
-
-
New York
-
Brooklyn、New York、美国、11201
- 招聘中
- NYU Langone Health
-
首席研究员:
- David Goddard
-
接触:
- Debra London
- 电话号码:617-802-6568
- 邮箱:Debra.London@nyulangone.org
-
-
Ohio
-
Cleveland、Ohio、美国、44195
- 尚未招聘
- EncompaSSc site in Cleveland, OH
-
接触:
- EncompaSSc contact
- 电话号码:617-802-6568
- 邮箱:EncompaSSc@mediartx.com
-
-
Oklahoma
-
Oklahoma City、Oklahoma、美国、73104
- 招聘中
- The University of Oklahoma Health Sciences Center
-
接触:
- Tiffany Moore
- 电话号码:405-271-3480
- 邮箱:OSCTR@ouhsc.edu
-
首席研究员:
- Aikaterini Thanou
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、美国、19107
- 尚未招聘
- EncompaSSc site in Philadelphia, PA
-
接触:
- EncompaSSc contact
- 电话号码:617-802-6568
- 邮箱:EncompaSSc@mediartx.com
-
Pittsburgh、Pennsylvania、美国、15219
- 招聘中
- University of Pittsburgh Medical Center
-
接触:
- UPMC
- 电话号码:617-802-6568
- 邮箱:kal128@pitt.edu
-
首席研究员:
- Christina Padilla
-
-
Texas
-
Allen、Texas、美国、75013
- 招聘中
- Stryde Research - DFW
-
首席研究员:
- John Lavery
-
接触:
- Moraima Avalos
- 电话号码:617-802-6568
- 邮箱:patients@stryderesearch.com
-
Dallas、Texas、美国、75246
- 招聘中
- Baylor Scott & White Research Institute
-
接触:
- Felicia Padilla
- 电话号码:617-802-6568
- 邮箱:felicia.padilla@bswhealth.org
-
首席研究员:
- Susan Mathai
-
Houston、Texas、美国、77030
- 尚未招聘
- EncompaSSc site in Houston, TX
-
接触:
- EncompaSSc contact
- 电话号码:617-802-6568
- 邮箱:EncompaSSc@mediartx.com
-
-
-
-
-
Coventry、英国、CV2 2DX
- 尚未招聘
- EncompaSSc site in Walsgrave Coventry, UK
-
接触:
- EncompaSSc contact
- 电话号码:617-802-6568
- 邮箱:EncompaSSc@mediartx.com
-
Liverpool、英国、L7 8XP
- 招聘中
- Royal Liverpool University Hospital
-
首席研究员:
- Marina Anderson
-
接触:
- EncompaSSc contact
- 电话号码:617-802-6568
- 邮箱:EncompaSSc@mediartx.com
-
London、英国、SW8 3RN
- 尚未招聘
- EncompaSSc site in London, UK
-
接触:
- EncompaSSc contact
- 电话号码:617 802 6568
- 邮箱:EncompaSSc@mediartx.com
-
Westcliff-on-Sea、英国、SS0 0RY
- 尚未招聘
- EncompaSSc site in Westcliff-on-Sea, UK
-
接触:
- EncompaSSc contact
- 电话号码:617-802-6568
- 邮箱:EncompaSSc@mediartx.com
-
-
-
-
-
Groningen、荷兰、9713 GZ
- 尚未招聘
- EncompaSSc site in Groningen, Netherlands
-
接触:
- EncompaSSc contact
- 电话号码:617-802-6568
- 邮箱:EncompaSSc@mediartx.com
-
-
-
-
-
Barcelona、西班牙、08003
- 尚未招聘
- EncompaSSc site in Barcelona, Spain
-
接触:
- EncompaSSc contact
- 电话号码:617-802-6568
- 邮箱:EncompaSSc@mediartx.com
-
Barcelona、西班牙、08025
- 尚未招聘
- EncompaSSc site in Barcelona, Spain
-
接触:
- EncompaSSc contact
- 电话号码:617-802-6568
- 邮箱:EncompaSSc@mediartx.com
-
Córdoba、西班牙、14004
- 尚未招聘
- EncompaSSc site in Córdoba, Spain
-
接触:
- EncompaSSc contact
- 电话号码:617-802-6568
- 邮箱:EncompaSSc@mediartx.com
-
Málaga、西班牙、29004
- 尚未招聘
- EncompaSSc site in Malaga, Spain
-
接触:
- EncompaSSc contact
- 电话号码:617-802-6568
- 邮箱:EncompaSSc@mediartx.com
-
Valencia、西班牙、46026
- 尚未招聘
- EncompaSSc site in Valencia, Spain
-
接触:
- EncompaSSc contact
- 电话号码:617-802-6568
- 邮箱:EncompaSSc@mediartx.com
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Diagnosis of diffuse cutaneous systemic sclerosis, classified according to 2013 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR)
-
Participant is either:
- Within 2 years of their first non-Raynaud's symptom and their mRSS is >7; OR
- >2 and ≤5 years from their first non-Raynaud's symptom, their mRSS is between 10 and 30, they are negative for the RNA polymerase 3 autoantibody, and (1) they have never had any previous spontaneous improvement in skin thickening of ≥4 points by mRSS on exams performed by the same clinician, or (2) they were never clinically noted to have a meaningful spontaneous reduction in skin thickness if mRSS was never done; OR
- >5 and ≤10 years from their first non-Raynaud's symptom, their mRSS is between >15 and ≤25, they are negative for the RNA polymerase 3 autoantibody, and (1) they have never had any previous spontaneous improvement in skin thickening of ≥4 points by mRSS, or (2) were never clinically noted to have a meaningful spontaneous reduction in skin thickness if mRSS was never done.
-
Participant is ≥18 years of age at time of signing the ICF.
-
Able to understand the study and provide a signed, written ICF
-
Able to read and understand the language of the ICF and other study-related materials
-
Forced vital capacity (FVCpp) of ≥45 pp10
-
Have diffusing capacity of the lungs for carbon monoxide (DLCO) of ≥30 percent predicted at Screening
-
Willing and able to complete all protocol-required study visits and procedures
-
Participants of childbearing potential must have a negative serum pregnancy test at Screening.
-
All participants with reproductive potential must agree to use and follow medically approved, highly effective methods of contraception during treatment and until 5 half-lives or 125 days after the last dose, whichever is longer
Exclusion Criteria:
-
Concomitantly have another serious medical illness, which, in the opinion of the Investigator, would interfere with the participant's ability to complete the study
-
Participant is currently on immunosuppressive therapy, systemic glucocorticoids or other antifibrotic agents detailed as follows:
- Immunosuppresive agents: Cyclophosphamide (IV or oral if used in the 6 months prior to Screening), calcineurin inhibitors (if used in the 30 days prior to Screening), azathioprine (if used in the 30 days prior to Screening), Janus-kinase inhibitors (if used in the 30 days prior to Screening), rituximab (if used in the 6 months prior to Screening), tocilizumab (if used in the 60 days prior to Screening) or any other biologic Disease-Modifying Antirheumatic Drugs (DMARD, if used in the last 30 days or 3 half-lives prior to Screening, whichever is longer)
- Antifibrotic agents: nintedanib or pirfenidone (if used in the 30 days prior to Screening). Also, exclusionary if used within 3 months of Screening are tyrosine-kinase inhibitors with recognized anti-fibrotic activity (imatinib, nilotinib, etc.)
- Systemic glucocorticoids: equivalent doses of prednisone greater than 10 mg/day (≤10 mg/day allowed). Has received any pulse intramuscular (IM) or intravenous (IV) steroid within 1 month of Screening
- Other agents:
i. mycophenolate mofetil unless on a stable dose for at least 6 months prior to Screening and there are no plans to adjust the dose during the study; ii. mycophenolic acid unless on a stable dose for at least 6 months prior to Screening and there are no plans to adjust the dose during the study; iii. hydroxychloroquine unless on a stable dose for at least 3 months prior to Screening and there are no plans to adjust the dose during the study; and iv. methotrexate unless on a stable dose for at least 3 months prior to Screening and there are no plans to adjust the dose during the study.
-
Previous or planned hematopoietic stem cell or solid organ transplantation
-
Previous treatment with chimeric antigen receptor (CAR)-T/CAR-NK therapy
-
Clinically significant PAH as determined by the Investigator at, or prior to first day of dosing (Baseline)
-
Current use of PAH medication (endothelin receptor antagonists, prostacyclin analogues, soluble guanylate cyclase stimulators) excluding calcium channel blockers and phosphodiesterase-5 inhibitors
-
Pregnant or currently breastfeeding
-
Aspartate transaminase (AST) or alanine transaminase (ALT) >2.0 upper limit of normal
-
Creatinine clearance <45mL/min
-
History of myocardial infarction, angina or congestive heart failure
-
International normalized ratio >2 or partial thromboplastin time >1.5 × upper limit of normal
-
Active infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
-
History of clinically significant thrombotic event within 12 months prior to Screening
-
Positive anticentromere antibody
-
Systemic sclerosis renal crisis within 12 months prior to Screening
-
Confirmed diagnosis of overlap syndrome, systemic lupus erythematosus with anti-double strand (ds)DNA antibody, rheumatoid arthritis with anti-cyclic citrullinated peptide (anti-CCP) antibody, or systemic sclerosis mimics (eosinophilic fasciitis, scleromyxedema) at the time of inclusion in the study
-
Known malignancy or history of malignancy within 5 years of Screening other than non-melanoma skin cancer and in situ cervical cancer
-
Major surgery within 8 weeks prior to Screening or planned surgery during study period
-
Unable to routinely access veins for blood draws and IV infusions
-
Currently receiving another experimental agent or participating in another clinical trial. If a participant has recently received another experimental agent, then the last dose must have been at least 5 half-lives or 30 days (whichever is longer) prior to Screening
-
History of myocardial infarction, angina or congestive heart failure
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
安慰剂比较:Placebo
Placebo |
Placebo |
|
实验性的:MTX-474
MTX-474 |
Dosage level: 4 mg/kg Unit dose strength: 50mg/ml MTX-474 is a human immunoglobulin G1 (IgG1) monoclonal antibody that binds the human EphrinB2 with high specificity and high affinity. MTX-474 is being developed as a therapy for patients with systemic sclerosis (SSc). |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change from baseline in Modified Rodnan Skin Score (mRSS)
大体时间:Baseline to week 24
|
Mean change from baseline to week 24 in the modified Rodnan Skin Score, a clinician-assessed measure of skin thickness across 17 body areas. Unit of measure: Score (range 0-51) |
Baseline to week 24
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Proportion of participants with a gene signature response in skin biopsy
大体时间:12 weeks
|
Proportion of participants in each arm (MTX-474 and placebo) demonstrating a dcSSc gene expression signature response on skin biopsy at Week 12. Unit of Measure: Participants (%) |
12 weeks
|
|
Number of participants with clinically significant findings on physical examination, vital signs, and clinical laboratory tests
大体时间:Baseline through end of study (week 28)
|
Number of participants with clinically significant findings on physical examination, vital signs, and clinical laboratory tests Unit of Measure: Participants (%) |
Baseline through end of study (week 28)
|
|
Number of participants with dose interruptions or treatment discontinuations due to adverse events
大体时间:Baseline through end of study (week 28)
|
Number of participants with dose interruptions or treatment discontinuations due to adverse events Unit of Measure: Participants (%) |
Baseline through end of study (week 28)
|
|
Safety and tolerability of MTX-474 in participants with dcSSc: Number of participants with treatment-emergent adverse events (TEAEs) and treatment-related adverse events (TRAEs)
大体时间:Baseline through end of study (week 28)
|
Incidence, seriousness, and severity of TEAEs and TRAEs as determined by investigator assessment. Unit of measure: Participants (%) |
Baseline through end of study (week 28)
|
|
Serum concentration of MTX-474 at sparse PK time points
大体时间:Baseline to week 28
|
Serum MTX-474 concentrations collected at predefined sparse PK time points to support population pharmacokinetic (popPK) analysis Unit of Measure: ng/mL |
Baseline to week 28
|
|
Clearance (CL) of MTX-474
大体时间:Baseline to week 28
|
Clearance of MTX-474 calculated from serial PK sampling using noncompartmental analysis Unit of Measure: L/hour |
Baseline to week 28
|
|
Terminal elimination half-life (t½) of MTX-474
大体时间:Baseline to week 28
|
Terminal elimination half-life of MTX-474 derived from serial PK sampling. Unit of Measure: Hours |
Baseline to week 28
|
|
Area under the plasma concentration-time curve (AUC) of MTX-474
大体时间:Baseline to week 28
|
AUC of MTX-474 calculated from serial PK sampling using noncompartmental analysis. Unit of Measure: ng·h/mL |
Baseline to week 28
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Proportion of participants with a response on the revised American College of Rheumatology Composite Response Index in Systemic Sclerosis (rACR-CRISS)
大体时间:Baseline to week 24
|
Proportion of participants achieving rACR-CRISS composite response Unit of Measure: Participants (%) |
Baseline to week 24
|
|
Change from baseline in Physician Global Assessment (PhGA) of disease status
大体时间:Baseline to week 24
|
Mean change from baseline to week 24 in the physician global assessment (phGA) of disease status in each arm Unit of Measure: Units on 0-10 visual analog scale (higher score = worse disease) |
Baseline to week 24
|
|
Change from baseline in Patient Global Assessment (PtGA) of disease status
大体时间:Baseline to week 24
|
Mean change from baseline to week 24 in the patient global assessment (PtGA) of disease status in each arm Unit of Measure: Units on 0-10 visual analog scale (higher score = worse disease) |
Baseline to week 24
|
|
Change from baseline in percent predicted forced vital capacity (FVCpp)
大体时间:Baseline to week 24
|
Mean change from baseline to week 24 on percent predicted forced vital capacity (FVCpp) Unit of Measure: Percent predicted (%) |
Baseline to week 24
|
|
Change from baseline in quantitative interstitial lung disease (QILD) score by high-resolution computed tomography (HRCT)
大体时间:Baseline to week 24
|
Mean change from baseline to week 24 in the QILD score by high resolution computed tomography scan (HRCT) in each arm Unit of Measure: Units on QILD score (0-100 scale; higher score = greater fibrosis) |
Baseline to week 24
|
|
Change from Baseline in free EphrinB2 levels
大体时间:Baseline to week 24
|
Median change from baseline to Week 24 in serum free EphrinB2 levels in each treatment arm. Unit of Measure: pg/mL |
Baseline to week 24
|
|
Change from baseline in forced vital capacity (FVC) by EphrinB2 levels
大体时间:Baseline to week 24
|
Mean change from baseline to Week 24 in FVC, analyzed by baseline EphrinB2 levels, in the subset of participants with interstitial lung disease (ILD). Unit of Measure: Percent predicted (%) |
Baseline to week 24
|
|
Proportion of participants achieving rACR-CRISS response by EphrinB2 levels
大体时间:Up to 24 weeks
|
Proportion of participants achieving a response on the revised ACR Composite Response Index in Systemic Sclerosis (rACR-CRISS), stratified by baseline EphrinB2 levels. Unit of Measure: Participants (%) |
Up to 24 weeks
|
|
To assess the presence, titer and impact of antidrug antibodies (ADA) against MTX-474
大体时间:Baseline to week 28
|
Samples will be collected from baseline until Week 28 to assess the rate at which antibodies develop to the study drug Unit of Measure: Titer units |
Baseline to week 28
|
|
Change from baseline in expression of total and phosphorylated EphB2, EphB3, and EphB4 receptors in skin
大体时间:Baseline to Week 12
|
Mean change from baseline to Week 12 in total and phosphorylated EphB2, EphB3, and EphB4 receptor expression in skin biopsy samples. Unit of Measure: Relative expression units (fold change from baseline) |
Baseline to Week 12
|
|
Change from baseline in transcriptomic profile
大体时间:Baseline to Week 12
|
Change from baseline to Week 12 in global transcriptomic profile via bulk RNA sequencing analysis of skin biopsies in each arm. Unit of Measure: Differential gene expression (log₂ fold change) |
Baseline to Week 12
|
|
Change from baseline in serum biomarkers of organ involvement
大体时间:Baseline to weeks 12 and 24
|
Change from baseline to Weeks 12 and 24 in serum levels biomarkers, including but not limited to, ProC3 and IL-6 associated with organ involvement Unit of Measure: ng/mL (or unit per biomarker) |
Baseline to weeks 12 and 24
|
|
Change from baseline in fatigue symptoms (FACIT-Fatigue score)
大体时间:Baseline to week 24
|
Mean change from baseline to Week 24 in fatigue symptoms as measured by the Functional Assessment of Chronic Illness Therapy-Fatigue Scale. Unit of Measure: Units on FACIT-Fatigue scale (range 0-52; higher score = less fatigue) |
Baseline to week 24
|
|
Change from baseline in gastrointestinal (GI) symptoms (UCLA SCTC GIT 2.0 score)
大体时间:Baseline to week 24
|
Mean change from baseline to Week 24 in GI symptom burden assessed by the UCLA SCTC GIT 2.0 questionnaire. Unit of Measure: Units on UCLA SCTC GIT 2.0 total score (range 0-3; higher score = worse symptoms) |
Baseline to week 24
|
|
Change from baseline in anxiety and depression symptoms (HADS)
大体时间:Baseline to week 24
|
Mean change from baseline to Week 24 in symptoms of anxiety and depression measured by the HADS instrument. Unit of Measure: Units on Hospital Anxiety and Depression Scale (HADS total and subscale scores; range 0-21 per subscale; higher score = worse symptoms) |
Baseline to week 24
|
|
Change from baseline in HAQ-DI
大体时间:Baseline to week 24
|
Mean change from Baseline in functional disability as assessed by HAQ-DI. Unit of measure: Score (0-3 scale) |
Baseline to week 24
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- MTX-474-S201
- 2025-523288-39 (EudraCT编号)
- 2025 (美国 NIH 拨款/合同)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.